share_log

Merck & Co | 8-K: Merck Announces Second-Quarter 2024 Financial Results

Merck & Co | 8-K: Merck Announces Second-Quarter 2024 Financial Results

默沙東 | 8-K:默沙東公佈 2024 年第二季度財務業績
美股SEC公告 ·  07/30 18:46

Moomoo AI 已提取核心訊息

Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the second quarter of 2024 on July 30, 2024. The company saw a 7% increase in total worldwide sales compared to the second quarter of 2023, reaching $16.1 billion. This growth was attributed to an 11% increase excluding the impact of foreign exchange. KEYTRUDA, Merck's cancer drug, experienced a 16% sales growth to $7.3 billion, with an even higher growth rate of 21% excluding foreign exchange influences. The company's GAAP earnings per share (EPS) was $2.14, while non-GAAP EPS was $2.28. Merck also highlighted the successful initial launch of WINREVAIR in the U.S. and positive opinions from the EU CHMP for adults with PAH. Additionally, the company completed acquisitions of EyeBio and Elanco's Aqua Business...Show More
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the second quarter of 2024 on July 30, 2024. The company saw a 7% increase in total worldwide sales compared to the second quarter of 2023, reaching $16.1 billion. This growth was attributed to an 11% increase excluding the impact of foreign exchange. KEYTRUDA, Merck's cancer drug, experienced a 16% sales growth to $7.3 billion, with an even higher growth rate of 21% excluding foreign exchange influences. The company's GAAP earnings per share (EPS) was $2.14, while non-GAAP EPS was $2.28. Merck also highlighted the successful initial launch of WINREVAIR in the U.S. and positive opinions from the EU CHMP for adults with PAH. Additionally, the company completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024. Merck raised its full-year 2024 financial outlook, expecting worldwide sales to be between $63.4 billion and $64.4 billion, and non-GAAP EPS to be between $7.94 and $8.04, reflecting a negative impact from a one-time charge for the acquisition of EyeBio. The company's chairman and CEO, Robert M. Davis, expressed pride in the team's efforts to advance the pipeline and deliver innovative solutions to medical needs.
2024年7月30日,領先的藥品公司默沙東公佈了2024年第二季度的財務業績。該公司全球銷售總額同比增長7%,達到161億美元。此增長歸因於匯率期貨影響除外銷售額增長11%。默沙東的抗癌藥物Keytruda的銷售額增長16%,達到73億美元,除匯率期貨影響外增長率更高達21%。公司的GAAP每股收益爲2.14美元,而非GAAP每股收益爲2.28美元。此外,默沙東在2024年7月完成了對EyeBio和Elanco水產業務的收購,並突出了WINREVAIR在美國的成功初期推出,得到了歐盟CHMP成人肺動脈高壓藥物正面意見。默沙東提高了其2024年全年財務預期,預計全球銷售額介於634億美元和644億美元之間,非GAAP每股收益預計介於7.94美元和8.04美元之間,反映了EyeBio收購的一次性收費的負面影響。公司的主席兼首席執行官羅伯特·M·戴維斯對團隊在推進項目和爲醫療需求提供創新解決方案方面所作出的努力感到自豪。
2024年7月30日,領先的藥品公司默沙東公佈了2024年第二季度的財務業績。該公司全球銷售總額同比增長7%,達到161億美元。此增長歸因於匯率期貨影響除外銷售額增長11%。默沙東的抗癌藥物Keytruda的銷售額增長16%,達到73億美元,除匯率期貨影響外增長率更高達21%。公司的GAAP每股收益爲2.14美元,而非GAAP每股收益爲2.28美元。此外,默沙東在2024年7月完成了對EyeBio和Elanco水產業務的收購,並突出了WINREVAIR在美國的成功初期推出,得到了歐盟CHMP成人肺動脈高壓藥物正面意見。默沙東提高了其2024年全年財務預期,預計全球銷售額介於634億美元和644億美元之間,非GAAP每股收益預計介於7.94美元和8.04美元之間,反映了EyeBio收購的一次性收費的負面影響。公司的主席兼首席執行官羅伯特·M·戴維斯對團隊在推進項目和爲醫療需求提供創新解決方案方面所作出的努力感到自豪。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息